CureVac.
biopharmaceutical company in Germany
- Reports this week
- 1
- Active events
- 1
- Connections
- 36
What's happening
Active this week
One to three months ago
Gone quiet
No new reports in 90+ days-
CureVac operates sites in the Netherlands, Belgium, Switzerland, and the U.S. (including Boston).Speculative1 report
-
GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.Some support1 report1 development inside
-
GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.Some support1 report
-
CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.Some support1 report1 development inside
No events began in the chosen period. Widen it, or reset.
Around CureVac this week
News at the entities that move CureVac most-
FDA StructuralThe FDA approved GSK's Jemperli drug, while Memorial Sloan Kettering Cancer Center was involved in the AZUR-1 trial.Moves CureVac
-
BioNTech StructuralUğur Şahin and Özlem Türeci plan to leave BioNTech, while Moderna and Merck advance their combined vaccine study.Moves CureVac
-
GSK OperationalSantander Group financed the Lorca Solar project, which secured power contracts from Haleon and GSK.Moves CureVac
-
Pfizer OperationalStudy results were presented by Tempus and Pfizer at the ESMO Congress, focusing on ongoing collaboration regarding diagnostic barriers.Moves CureVac
-
CRISPR Therapeutics Mentioned togetherCRISPR Therapeutics and Vertex Pharmaceuticals received FDA approval for their gene therapy Casgevy for sickle cell disease.Moves CureVac
-
Boston Shared contextFed's Beige Book reports rising costs and supply chain pressures in the Boston and Dallas districts.Moves CureVac
Connections
The 7 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BioNTech Structural
BioNTech acquired CureVac, making it a wholly owned subsidiary to strengthen its mRNA cancer immunotherapy portfolio.
-
GSK Operational
CureVac and GSK have established an operational partnership involving the sale of vaccine rights and shared involvement in legal disputes.
-
FDA Structural
FDA formally regulates and grants clearance for CureVac's clinical trials and IND applications.
-
Pfizer Operational
The companies are actively competing and engaged in legal disputes over mRNA vaccine patents.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports on CureVac's analyst ratings and company developments.
-
CRISPR Therapeutics Mentioned together
Both companies are co-mentioned as operating within the biopharmaceutical healthcare sector.
-
Boston Shared context
CureVac operates and maintains a business presence within the city of Boston.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
1 eventAugust 2026
1 eventShow 1 earlier month
June 2026
5 events- BioNTech acquired CureVac for mRNA technology and entered a collaboration to co-develop BNT327.
- CureVac operates sites in the Netherlands, Belgium, Switzerland, and the U.S. (including Boston).
- GSK and CureVac are involved in a German patent dispute, alongside settlements regarding mRNA vaccine technology involving Pfizer, leading to FDA priority review for an oral antibiotic.
- GSK and CureVac reached a settlement regarding patent disputes, with Pfizer covering part of the payouts.
- CureVac announced updates from Tübingen and Boston, leading to EMA granting CTA clearance for CVHNLC based on mRNA vaccine patents.